Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
Back to media releases Next media release LONDON,Jan. 7,2025-- Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflorni